Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Michael Ciarametaro"'
Publikováno v:
MDM Policy & Practice, Vol 5 (2020)
Purpose. Assess patient preferences for aspects of breast cancer treatments to evaluate and inform the usual assumptions in scoring rubrics for value frameworks. Methods. A discrete-choice experiment (DCE) was designed and implemented to collect quan
Externí odkaz:
https://doaj.org/article/ac7bd53508bd4e4685060378954844bb
Autor:
Marcia R. Weaver, Jonah Joffe, Michael Ciarametaro, Robert W. Dubois, Abe Dunn, Arjun Singh, Gianna W. Sparks, Lauryn Stafford, Christopher J. L. Murray, Joseph L. Dieleman
Publikováno v:
Health Affairs. 41:994-1004
Autor:
William Herring, Michael Ciarametaro, Josephine Mauskopf, David Wamble, Brian Sils, Robert Dubois
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 22:529-541
The study estimated the extent to which drug innovations over the past 30 years may have improved outcomes for six diseases.We analyzed six diseases (ischemic heart disease, lung cancer, breast cancer, human immunodeficiency virus [HIV] infection, ty
Publikováno v:
The American journal of managed care. 28(9)
In the health spending debate, what policy makers need most is an honest, realistic, and evidence-based discussion. Unfortunately, many studies in the public arena fall far short.
Publikováno v:
Value in Health. 24:388-396
Objectives Various strategies to address healthcare spending and medical costs continue to be debated and implemented in the United States. To date, these efforts have failed to adequately contain the growth of healthcare cost. An alternative strateg
Publikováno v:
Journal of managed carespecialty pharmacy. 28(2)
BACKGROUND: Rising health care spending has sparked new efforts to constrain health care expenditures. OBJECTIVE: To explore how health care spending is distributed across consumers and how utiliza...
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:66-71
Developments in diagnostics, medical devices, procedures, and prescription drugs have increased life expectancy and quality of life after diagnosis for many diseases. Previous research has shown that, overall, increased investment in medical technolo
Autor:
Joshua T. Cohen, Peter J. Neumann, James D. Chambers, Robert W. Dubois, Michael Ciarametaro, E Pope, Kathy Bungay
Publikováno v:
Value in Health. 21:400-406
Background Differences in payer evaluation and coverage of pharmaceuticals and medical procedures suggest that coverage may differ for medications and procedures independent of their clinical benefit. We hypothesized that coverage for medications is
Autor:
Dorothy Hoffman, Tricia Lee Wilkins, Shirley Reitz, Melanie D Whittington, Jeremy Fredell, Paul L. Jeffrey, Jeff Myers, Paul Miner, Joe Vandigo, William Rogers, Collin Conway, Genia Long, Seth S. Martin, Sunil Majethia, Jason Spangler, Donna Moncuso, Barbara Henry, Robin Turpin, Jane Barlow, Louis Tharp, Laura M. Koontz, Cynthia Bens, Stephen George, Ana Stojanovska, Kyle Skiermont, Scott Jauch, Annette Powers, Bill Martin, Tim Brent, Michael Ciarametaro, Bonnie Shaul, Susan Trieu, Pamela Keith, Matthew Harman
Publikováno v:
Journal of managed carespecialty pharmacy. 25(2)
High-investment medications, such as gene therapy and innovative specialty medications, offer breakthrough treatments that can greatly improve outcomes to patients with serious health conditions. However, many of these therapies are associated with s
Publikováno v:
Health affairs (Project Hope). 38(1)
The continued rise in health care spending has led to an intense debate among policy makers and other health care stakeholders on how to best manage increasing costs, leading to a focus on cost increases with little consideration of the associated ch